Sinovac Biotech vs Zai Lab
SVA and ZLAB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How SVA and ZLAB compare
Sinovac Biotech grew revenue faster over the last twelve months (6.8% versus 0.02% for Zai Lab).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | SVA | ZLAB |
|---|---|---|
| Size and price | ||
| Market cap | – | $38.2B |
| Share price | $6.47 | $24.60 |
| Change, 1 year | 0.00% | 12.4% |
| Change, 5 years | 0.00% | −70.8% |
| Beta (5Y) | 0.00 | 1.10 |
| Employees | 2,602 | 1,784 |
| StockData Score | ||
| Total score | 6 | 6 |
| Valuation score | 0 | 0 |
| Growth score | 1 | 1 |
| Performance score | 0 | 3 (better) |
| Health score | 5 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 86.5× |
| P/B | – | 67.8× |
| FCF yield | – | −0.43% |
| Fair value | – | $4.31 |
| Margin of safety | – | −471% |
| Growth | ||
| Revenue growth (TTM) | 6.8% (better) | 0.02% |
| Revenue growth, 5Y average | −5.4% | 56.5% (better) |
| EPS growth (TTM) | −165% | – |
| Profitability | ||
| Gross margin | 67.9% (better) | 54.7% |
| Operating margin | −127% | −63.0% (better) |
| Net margin | – | −44.9% |
| FCF margin | −145% | −37.0% (better) |
| Return on equity | – | −30.0% |
| Return on invested capital | – | −87.6% |
| Financial health | ||
| Debt / equity | 0.00 | 0.45 (better) |
| Interest coverage | – | −45.2× |
| Current ratio | 4.59 (better) | 2.04 |
| Altman Z-score | – | 46.02 |
| Piotroski F-score | – | 4 |
| Dividends and buybacks | ||
| Years of dividend growth | 0 | – |
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 14.6% | 2.8% |
| Held by insiders | 65.7% | 0.67% |
| Insider net buying, 12 months | – | −$10.8M |
| Short interest, % of float | 0.33% | – |
Go deeper
- SVA stock overview
- SVA income statement
- SVA valuation and score
- ZLAB stock overview
- ZLAB income statement
- ZLAB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.